Valuation : Centessa Pharmaceuticals plc

Market Cap 626.66Cr 539.93Cr 511.24Cr 463.39Cr 869.35Cr 60TCr 873.75Cr 6.07TCr 2.33TCr 30TCr 2.35TCr 2.3TCr 96TCr P/E 2024
-8.13x
P/E 2025 -17.2x
Enterprise Value 609.04Cr 524.75Cr 496.87Cr 450.36Cr 844.91Cr 58TCr 849.19Cr 5.9TCr 2.27TCr 30TCr 2.29TCr 2.24TCr 94TCr EV / Sales 2024
-
EV / Sales 2025 23,18,10,355x
Free-Float
78.43%
Yield 2024 *
-
Yield 2025 -
1 day+0.80%
3 months+1.84%
6 months+43.52%
Current year+61.94%
Current year 21.5
Extreme 21.5
40.56
1 year 17.05
Extreme 17.05
40.56
3 years 5.15
Extreme 5.15
40.56
5 years 2.88
Extreme 2.885
40.56
10 years 2.88
Extreme 2.885
40.56
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/10/2024
Chief Tech/Sci/R&D Officer 55 01/03/2023
Chief Administrative Officer 58 01/04/2021
Director TitleAgeSince
Director/Board Member - 24/06/2026
Director/Board Member - 24/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
24/06/26
Medicxi Ventures (Jersey) Ltd.
SellCompany -1,99,63,157 12.9020%
01/05/26 Tax

Chief Executive Officer

-604 0.0004%
26/03/26 Exercice

Executive/Senior Manager

71,994 0.0539%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%-.--%+78.65%+517.38% 626.65Cr
-0.71%-6.35%-4.87%+9.03% 4.61TCr
+0.21%-2.98%+340.68%+519.93% 4.36TCr
+1.74%-2.24%+37.28%+21.57% 4.24TCr
+1.38%-3.28%+3.23%+65.60% 3.89TCr
-1.44%-5.26%+8.78%+36.85% 3.22TCr
+0.87%-2.60% - - 1.72TCr
+0.75%-0.64%+18.07%+110.32% 1.63TCr
-0.31%-2.78%+10.47%+30.49% 1.43TCr
+1.93%-3.55%+74.20%+39.37% 1.3TCr
Average +0.52%-3.61%+62.94%+150.06% 2.7TCr
Weighted average by Cap. +0.41%-4.36%+73.19%+133.27%

Financials

2024 2025
Net sales - 15 12.92 12.24 11.09 20.81 1.43T 20.91 145.34 55.89 729.06 56.33 55.1 2.3T
Net income -24Cr -20Cr -19Cr -17Cr -33Cr -2.25TCr -33Cr -228.43Cr -88Cr -1.15TCr -89Cr -87Cr -3.62TCr -20Cr -17Cr -16Cr -15Cr -27Cr -1.89TCr -28Cr -191.4Cr -74Cr -960.09Cr -74Cr -73Cr -3.03TCr
Net Debt -36Cr -31Cr -30Cr -27Cr -51Cr -3.48TCr -51Cr -353.03Cr -135.76Cr -1.77TCr -136.83Cr -133.83Cr -5.6TCr -18Cr -15Cr -14Cr -13Cr -24Cr -1.68TCr -25Cr -170.73Cr -66Cr -856.4Cr -66Cr -65Cr -2.71TCr
Logo Centessa Pharmaceuticals plc
Centessa Pharmaceuticals Limited, formerly Centessa Pharmaceuticals plc, is a clinical-stage pharmaceutical company, developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It has an early-stage immuno-oncology program focused on its LockBody technology platform. The OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1, NT2 and idiopathic hypersomnia. ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Employees
129
  1. Stock Market
  2. Stocks
  3. CNTA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!